Clinical Trial Detail

NCT ID NCT03326752
Title Phase 1b Dose Escalation and Dose Expansion Trial
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dynavax Technologies Corporation
Indications

lung non-small cell carcinoma

Therapies

DV281

Age Groups: adult senior

No variant requirements are available.